XML 24 R8.htm IDEA: XBRL DOCUMENT

Revenue Recognition	9 Months Ended
Revenue Recognition	Sep. 30, 2016
Accounting Policies [Abstract]
Revenue Recognition	Revenue Recognition The Company is currently a party to a collaboration agreement with Genentech, the terms of which provide for Genentech to make a non-refundable license fee payment, research and development funding payments, contingent cash payments based upon achievement of clinical development and regulatory objectives, and royalties on product sales. For a complete discussion of the Company’s revenue recognition policy, see Note 2(c) included in its 2015 Annual Report on Form 10-K.